FOXM1 and Stroke: Notably, our study not only validates FoxM1 as a key downstream effector of hAECs-Exos but also positions it as a superior target compared to canonical stroke-related transcription factors, offering a more comprehensive strategy for interrupting the ischemic cascade and improving stroke outcomes.